🇺🇸 FDA
Patent

US 11850261

Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells

granted A61KA61K35/12A61P

Quick answer

US patent 11850261 (Methods of producing human RPE cells and pharmaceutical preparations of human RPE cells) held by Astellas Institute for Regenerative Medicine expires Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Astellas Institute for Regenerative Medicine
Grant date
Tue Dec 26 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 21 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K35/12, A61P, A61P27/02